An order given by US District Judge William Young in a big-pharma antitrust case has appointed lead counsel to the case, but not without pointing out what he called “unseemly squabble” among the plaintiffs’ firms over who would win that lead. The suit concerns AstraZeneca which, along with three other generic drug makers, drug wholesalers have accused of colluding together to keep AstraZeneca’s heartburn drug Nexium off the sheves. Judge Young appointed the Hagens Berman Sobol Shapiro group to lead the case, but not without harshly commenting on the fight for the lead, in which Grant & Eisenhofer, Garwin Gerstein & Fisher and Berger & Montague also took part. In the words of Judge Young, the fight between the firms was more about who would be awarded the most attorneys’ fees rather than who was best-suited to lead the antitrust case.
Full Content: Thomson Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
ConocoPhillips Acquires Marathon Oil for $22.5 Billion in Major Energy Sector Consolidation
May 29, 2024 by
CPI
Judge Denies Amazon’s Bid to Dismiss FTC Lawsuit Over Prime Membership Practices
May 29, 2024 by
CPI
Germany and France Advocate for Major EU Competition Reform
May 29, 2024 by
CPI
Equifax Accused of Monopolizing Employment Verification Market in New Suit
May 29, 2024 by
CPI
Car Battery Makers to Challenge EU Cartel Charges in Brussels
May 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI